Research Paper Volume 13, Issue 13 pp 17638—17654
Pretreatment neutrophil-to-lymphocyte ratio predicts the benefit of gastric cancer patients with systemic therapy
Figure 4. Forest plot for the HRs of progression-free survival (PFS) in gastric cancer patients with systemic therapy between low and high pretreatment NLR. “D+L” means DerSimonian and Laird method. “I-V” means generic inverse variance method.